Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48

Benzinga Newsdesk www.benzinga.com Positive 84.8%

Neg 0% Neu 0% Pos 84.8%

Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.